Bellamy's Australia Ltd (ASX:BAL) shares sink lower on disappointing AGM update

The Bellamy's Australia Ltd (ASX:BAL) share price has sunk lower on Wednesday following the release of a disappointing AGM update…

| More on:

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

a woman

In morning trade the Bellamy's Australia Ltd (ASX: BAL) share price has sunk lower following the release of a trading update ahead of its annual general meeting.

At the time of writing the infant formula company's shares are down 6% to $7.99.

What was in the update?

According to the release, Bellamy's has been operating in a challenging trading environment and has seen slower China cross-border growth across the infant formula category and increased competition from both local and global competitors.

The good news is that management believes that these are only short-term challenges and are likely to relate to lower birth rates in Tier 1 and 2 cities. In China. It expects to overcome these challenges with greater Tier 3 and Tier 4 ecommerce penetration and continued investment in its brand and product portfolio.

Based on recent trading, management expects Australian label full year revenue growth at the low end of its 0% to 10% range. This is due to a soft first half where sales are expected to be down 10% to 15% on the prior corresponding period because of a $10 million to $15 million run-down of trade inventory prior to rollout of its brand upgrade.

As you may have noticed, the guidance above is purely for its Australian label products as Bellamy's has still not been given its SAMR (formerly known as CFDA) accreditation to sell Chinese label products.

Management provided an update on its application. It stated:

"As outlined in August, our SAMR registration for Chinese-label product was submitted in December and is in progress. We remain confident in our technical application but do not yet have transparency of timing for approval. We continue to plan for successful registration and are building out a detailed China offline strategy in parallel for speedy and successful execution on approval."

I'm very surprised at how long it has taken, but I am optimistic that it will occur before the end of the first half. If this does happen then it is likely to give its second half performance a major lift.

Should you invest?

While I think that Bellamy's and A2 Milk Company Ltd (ASX: A2M) will be a great long-term investments, I suspect Bellamy's shares will remain under pressure until it announces its SAMR registration.

This may mean that better entry points will present themselves in the coming weeks or months, depending on how long it takes for this to be granted.

Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia owns shares of A2 Milk. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Share Fallers

An arrow crashes through the ground as a businessman watches on.
Share Fallers

After falling 43% in a week, are Cochlear shares now a buy?

Is this drop a warning sign?

Read more »

Disappointed man with his head on his hand looking at a falling share price his a laptop.
Share Fallers

Why Brainchip, Fortescue, IGO, and Life360 shares are tumbling today

These shares are ending the week in the red. But why?

Read more »

a woman sits next to her computer screen with her head in her hands with the screens slowing graphs on downward trajectories.
52-Week Lows

Can the beaten-down CSL share price ever reach $300 again?

CSL is near decade lows. Can it ever climb back?

Read more »

An arrow crashes through the ground as a businessman watches on.
Healthcare Shares

Cochlear stock down 40%: How much has this cost ASX investors?

One day can ruin years of success...

Read more »

Bored man sitting at his desk with his laptop.
Share Fallers

Why Black Cat, Mirvac, Qantas, and Temple & Webster shares are falling today

These shares are having a tough session. But why?

Read more »

A male investor wearing a blue shirt looks off to the side with a miffed look on his face as the share price declines.
Share Fallers

Why Bank of Queensland, Cochlear, Northern Star, and Paladin Energy shares are falling today

These shares are having a difficult time on hump day. But why?

Read more »

An older man wearing glasses and a pink shirt sits back on his lounge with his hands behind his head and blowing air out of his cheeks.
Share Fallers

Why ANZ, Challenger, Hub24, and Lynas shares are dropping today

These shares are under pressure on Tuesday. But why?

Read more »

A man sits in despair at his computer with his hands either side of his head, staring into the screen with a pained and anguished look on his face, in a home office setting.
Share Fallers

Why Monash IVF, NAB, Viva Energy, and Worley shares are falling today

These shares are starting the week in the red. But why?

Read more »